NCT00699452 - The Potential of Candesartan to Retard the Progression of Aortic Stenosis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2014

Conditions

Aortic Valve Stenosis

Interventions

DRUG

candesartan

Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)

DRUG

placebo

Trial Locations (1)

RECRUITING

Division of Cardiology, Helsinki University Central Hospital, Helsinki